

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**WUXI APPTEC CO., LTD.\***  
**無錫藥明康德新藥開發股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*  
**(Stock Code: 2359)**

**POSITIVE PROFIT ALERT**

This announcement is published by the Company simultaneously on the Shanghai Stock Exchange pursuant to the Rules Governing the Listing of Stocks on Shanghai Stock Exchange and on The Stock Exchange of Hong Kong Limited pursuant to the disclosure obligations under Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). The Board hereby announces that the Company is expecting to record an increase in the revenue and net profit attributable to shareholders of the Company for the year ended December 31, 2025 in comparison with the corresponding period in the year of 2024.

**Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.**

This announcement is published by WuXi AppTec Co., Ltd.\* (無錫藥明康德新藥開發股份有限公司) (the “**Company**”) simultaneously on the Shanghai Stock Exchange pursuant to the Rules Governing the Listing of Stocks on Shanghai Stock Exchange and on The Stock Exchange of Hong Kong Limited pursuant to the disclosure obligations under Rule 13.09(2) (a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). The board of directors of the Company (the “**Board**”) hereby announces that the Company (together with its subsidiaries, the “**Group**”) is expecting to record an increase in the revenue and net profit attributable to shareholders of the Company for the year ended December 31, 2025 (the “**Current Period**”) in comparison with the corresponding period in the year of 2024 (the “**Corresponding Period**”). The estimated financial data disclosed in this announcement is based on preliminary accounting information prepared under the China Accounting Standards for Business Enterprises.

## **Important Notice:**

The Company maintains a laser focus on the Company's unique, integrated and end-to-end CRDMO (Contract Research, Development and Manufacturing Organization) business model. In response to customers' ongoing demand for enabling services, the Company continues to enhance its capabilities and capacity, optimize production processes and improve operating efficiency. These factors are driving sustained long-term business growth, delivering highly efficient and exceptional services to customers and helping to bring groundbreaking therapies to patients worldwide.

1. The revenue of the Company was expected to be approximately RMB45,456.17 million for the Current Period, representing a year-over-year increase of approximately 15.84%, revenue from continuing operations representing a year-over-year increase of approximately 21.40%.
2. The adjusted non-IFRS net profit attributable to the owners of the Company (the "**Adjusted Net Profit**") was expected to be approximately RMB14,956.55 million for the Current Period, representing a year-over-year increase of approximately 41.33%.
3. The net profit attributable to the owners of the Company after deducting non-recurring gain or loss items was expected to be approximately RMB13,240.56 million for the Current Period, representing a year-over-year increase of approximately 32.56%, compared with the Adjusted Net Profit increase rate, mainly affected by exchange rate fluctuations.
4. The net profit attributable to the owners of the Company was expected to be approximately RMB19,150.58 million for the Current Period, representing a year-over-year increase of approximately 102.65%, including the investment income from sale of a partial interest in an associate and from divestiture of certain business; and the basic earnings per share was expected to be approximately RMB6.70 per share for the Current Period, representing a year-over-year increase of approximately 104.27%.

## **I. ESTIMATED RESULTS FOR THE CURRENT PERIOD**

### **(1) Period to which the estimated results apply**

January 1, 2025 to December 31, 2025.

**(2) Estimated Results**

1. The revenue of the Company was expected to be approximately RMB45,456.17 million for the Current Period, representing a year-over-year increase of approximately 15.84%, revenue from continuing operations representing a year-over-year increase of approximately 21.40%.
2. The Adjusted Net Profit was expected to be approximately RMB14,956.55 million for the Current Period, representing a year-over-year increase of approximately 41.33%.
3. The net profit attributable to the owners of the Company after deducting non-recurring gain or loss items was expected to be approximately RMB13,240.56 million for the Current Period, representing a year-over-year increase of approximately 32.56%, compared with the Adjusted Net Profit increase rate, mainly affected by exchange rate fluctuations.
4. The net profit attributable to the owners of the Company was expected to be approximately RMB19,150.58 million for the Current Period, representing a year-over-year increase of approximately 102.65%; the total profit of the Company was expected to be approximately RMB23,906.15 million for the Current Period, representing a year-over-year increase of approximately 107.16%; and the basic earnings per share was expected to be approximately RMB6.70 per share for the Current Period, representing a year-over-year increase of approximately 104.27%.

**(3) The estimated operating results have not been audited or reviewed by a certified public accountant.**

**II. RESULTS OF THE CORRESPONDING PERIOD IN THE YEAR OF 2024**

- (1) Revenue of the Company: RMB39,241.43 million. Adjusted Net Profit: RMB10,582.52 million. Net profit attributable to the owners of the Company after deducting non-recurring gain or loss items: RMB9,988.10 million. Net profit attributable to the owners of the Company: RMB9,450.31 million. Total profit of the Company: RMB11,539.81 million.
- (2) Basic earnings per share: RMB3.28 per share.

### **III. MAIN REASONS FOR THE ESTIMATED GROWTH IN RESULTS FOR THE CURRENT PERIOD**

#### **(1) Impact of the principal business**

The Company maintains a laser focus on the Company's unique, integrated and end-to-end CRDMO (Contract Research, Development and Manufacturing Organization) business model. In response to customers' ongoing demand for enabling services, the Company continues to enhance its capabilities and capacity, optimize production processes and improve operating efficiency. These factors are driving sustained long-term business growth, delivering highly efficient and exceptional services to customers and helping to bring groundbreaking therapies to patients worldwide.

#### **(2) Impact of non-recurring gain or loss**

The impact of the non-recurring gain or loss items on net profit attributable to the owners of the Company for the Current Period is primarily attributable to the investment income generated by: sale of a partial interest in WuXi XDC Cayman Inc. with net profit expected to be approximately RMB4,160.86 million; and disposal of all shares in WuXi Clinical Development Services (Shanghai) Co., Ltd. and WuXi MedKey Med-Tech Development (Shanghai) Co., Ltd. with net profit expected to be approximately RMB1,433.79 million.

### **IV. RISK WARNING**

There are no significant uncertainties pertaining to the Company which may affect the accuracy of the estimated results. The estimated operating results have not been audited or reviewed by a certified public accountant.

### **V. OTHER INFORMATION**

The Board would like to remind the investors that the above estimated results of the Company for the year ended December 31, 2025 were prepared based on preliminary accounting information only. Please refer to the announcement of the audited 2025 annual results of the Company to be published subsequently for the finalized financial figures. Investors are advised to pay attention to the investment risks.

**Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.**

By order of the Board  
**WuXi AppTec Co., Ltd.\***  
**Dr. Ge Li**  
*Chairman*

Hong Kong, January 12, 2026

*As of the date of this announcement, the Board comprises Dr. Ge Li, Dr. Minzhang Chen, Dr. Steve Qing Yang and Mr. Zhaohui Zhang as executive Directors, Mr. Xiaomeng Tong and Dr. Yibing Wu as non-executive Directors and Ms. Christine Shaohua Lu-Wong, Dr. Wei Yu, Dr. Xin Zhang, Ms. Zhiling Zhan and Mr. Xuesong Leng as independent non-executive Directors.*

*\* For identification purposes only*